NOVELTY & IMPACT: Treatment-induced tumor vascular normalization is a common phenomenon but poorly understood. Differential VEGF isoform expression strongly influences vascular morphology and function. Using intravital microscopy, we found that the soluble 120 isoform of VEGF is associated with tumor susceptibility to vascular normalization induced by VEGFR-2-targeted treatment. Furthermore, normalization rendered tumor blood vessels resistant to subsequent treatment with the archetypal vascular disrupting agent, CA4P. Results suggest VEGF isoform expression can predict for tumor response to vascular-targeted therapy.
ABBREVIATIONS USED: ANOVA (analysis of variance); α-SMA (alpha smooth muscle actin); CA4P (combretastatin A4 3-O-phosphate); CD31 (cluster differentiation 31 / platelet endothelial cell adhesion molecule); c-RET (intrinsic rearranged-during-transfection protein); DAB (3,3'-diaminobenzidine; DMEM (Dulbecco's minimal essential medium); DMSO (dimethyl sulfoxide); Flk1 (fetal liver kinase 1); Flt1 (Fms-like tyrosine kinase 1); Flt3 (Fms-like tyrosine kinase 3); GIST (gastro-intestinal stromal tumors); HRP (horseradish peroxidase); IFP (interstitial fluid pressure); KDR (kinase insert domain receptor) NSCLC (non-small cell lung cancer); PDGFR-β (platelet derived growth factor receptor beta); pERK (phosphorylated extra-cellular signal-regulated kinases); RCC (renal cell carcinoma); RCV (red cell velocity); RTK (receptor tyrosine kinase); SCID (severe combined immune deficient); stem cell growth factor receptor/c-Kit (SCF R), VDA (vascular disrupting agent); VEGF (vascular endothelial growth factor A); VEGFR-2 (VEGF receptor 2).
Introduction
Vascular endothelial growth factor-A (VEGF) is a key stimulator of tumor angiogenesis and the most well-studied target for anti-angiogenic therapy 1, 2 . Anti-VEGF monotherapy has been approved in a limited number of clinical settings, notably in advanced renal cell carcinoma. However, most success has been achieved by combining VEGF-targeted treatments with chemotherapeutic drugs 2 . VEGF inhibition can effectively block tumor angiogenesis and slow tumor growth in mouse models of cancer 3 . However, in animal models it has been shown also that there is a dose and time window at which vascular 'normalization' occurs following antiangiogenic therapy, involving re-modelling of the vasculature resulting in improved delivery of oxygen and therapeutic drugs to tumor tissue 4, 5 . Detecting tumor vascular normalization in the clinic is challenging, requiring sophisticated imaging technology to monitor vascular morphology and function. Nevertheless, this phenomenon has been reported clinically with both the monoclonal antibody to VEGF, bevacizumab (Avastin; Genentech) 6 , and the VEGF receptor tyrosine kinase (RTK) inhibitor, cediranib (Recentin; AstraZeneca) 7 . If vascular normalization proves to be a common phenomenon in human tumors during/following antiangiogenic therapy, it could potentially explain the beneficial combination of antiangiogenic treatment with chemotherapy and provide further possibilities for therapeutic exploitation. In order for rational therapeutic exploitation to occur, further information is required regarding the nature of this phenomenon and its influence on subsequent therapy.
RTK inhibitors form a large group of anti-cancer agents, many of them developed as anti-angiogenic agents targeted against VEGFR-2 (flk-1/KDR) but with a range of target specificities. SU5416 (semaxinib) is an indolinone, developed by Sugen as a VEGFR-2 inhibitor, which binds to the tyrosine kinase domain of the receptor 8 . It acts as an ATP-mimetic and is the predecessor of SU11248 (sunitinib or Sutent), which is approved for treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumors (GIST) as monotherapy. Experiments using both cellfree and cellular systems have shown that SU5416 inhibits other receptor tyrosine kinases, in addition to VEGFR-2, such as c-Kit, Flt3, c-MET and PDGFR, with variable potencies [8] [9] [10] [11] although the complete specificity profile of SU5416, as for its related compounds, is unknown 12 . SU5416 has been withdrawn from clinical testing but is a useful exemplar of a class of RTK inhibitors with activity against VEGFR-2 and ability to induce tumor vascular normalization 13, 14 .
It is increasingly recognised that differential gene-splicing of VEGF gives rise to variations in vascular patterning in both normal embryology 15 and tumor angiogenesis 16, 17 . The most prevalent VEGF protein isoforms consist of 121, 165
and 189 amino acids in the human and 120, 164 and 188 in the mouse 18 . These isoforms differ in molecular mass, solubility and heparin-binding affinity but all interact with the VEGF receptors, Flt1 (VEGFR-1) and Flk1/KDR (VEGFR-2) 19 . All three isoforms can be found in human tumor tissue, with VEGF121 (soluble isoform) and 165 commonly the most prevalent 20, 21 . Despite this prevalence, clinical studies suggest that the balance between all three isoforms is important for driving tumor angiogenesis and progression. For instance, matrix-bound VEGF189 expression has been reported to associate with increased vascularity, progression and prognosis in non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC) and colorectal carcinomas [22] [23] [24] , whereas the soluble isoforms were reported to be associated with metastasis in melanoma and squamous cell carcinoma of the head and neck 25, 26 .
There is mounting evidence that the different VEGF isoforms can differentially signal, perhaps due to their diverse abilities to bind co-receptors of VEGFR-2 such as the neuropilins, integrins and heparan sulphate proteoglycans 27 . This implies that VEGF isoform expression could also influence response to specific treatments.
However, little is known about this aspect of VEGF tumor biology and, in particular, nothing is known about how vascular patterning and function determines susceptibility to vascular normalization. Using mouse fibrosarcoma cell lines developed to express only single isoforms of VEGF under endogenous promoter control, we found that the corresponding solid tumors expressed the relevant isoforms and had disparate vascular characteristics, making them useful models for investigating factors associated with the process of vascular normalization induced by anti-angiogenic treatment 17 .
The aims of the current study were i) to determine whether differential expression of individual VEGF isoforms (VEGF120 and VEGF188) which predicate for diverse tumor vascular morphology and function, is associated with differential susceptibility to normalization (morphological and functional end-points) following treatment with an archetypal receptor tyrosine kinase inhibitor (SU5416) and, if normalization occurs, ii) to determine how this process affects subsequent vascular susceptibility to disruption by a typical tubulin-binding VDA (CA4P). We reasoned that VEGF120-expressing tumors would be particularly susceptible to vascular normalization and that this would alter their response to CA4P.
Methods
All experiments were conducted in accordance with the United Kingdom Home
Office Animals (Scientific Procedures) Act 1986, with local ethical approval and in line with recently published guidelines 28 . CA4P was kindly provided by Professor GR Pettit, Arizona State University.
VEGF isoform-specific tumor cell lines
In-house-developed mouse fibrosarcoma cell lines, which produce only single isoforms of VEGF (120 and 188), under endogenous promoter control, were used in this study 17 . Cells were maintained in high glucose DMEM (Invitrogen, Paisley, UK) media containing L-glutamine, fetal calf serum, and the antibiotics G-418 and puromycin. Previous investigations showed that only the relevant VEGF isoforms were produced from each isoform-specific cell line 17 . 
Subcutaneous tumor transplantation and tumor growth

Immunohistochemistry and histology
Tumor-bearing mice were treated with SU5416 or vehicle, as described above, when tumors reached 6-7 mm in diameter. Some mice also received CA4P (100 mg/kg at 10 ml/kg i.p.) or saline vehicle, 21 h after the second dose of SU5416. and pimonidazole staining respectively. Sections were exposed to the primary antibody overnight at 4°C and standard signal amplification was achieved using an avidin-biotin complex (ABC)/horseradish peroxidase system (Vectastain, Vector
Laboratories, Burlingame, CA, USA). The signal was visualized with DAB (Dako, Ely, UK) and sections were counterstained with haematoxylin.
CD31 staining in viable tumor regions was quantitatively analysed using an inhouse-developed segmentation algorithm to determine morphological characteristics of tumor vasculature 30 . Additional formalin-fixed sections were stained with haematoxyin and eosin for necrosis scoring, whereby whole tumor sections were scanned by hand using a Nikon Optiphot-2 microscope and x20 objective. Using an eye-piece graticule marked with 25 random points (Chalkley grid) and blinded to the experimental groups, the observer counted the number of points falling on necrotic
tissue. This number, as a % of total points counted, equated to necrosis, as a % of the total sectional area. Tissue sections were scanned at high power using an Aperio slide scanner (ScanScope, Aperio ePathology Solutions, Oxford, UK) for hypoxia analysis.
Viable tumor regions were outlined and % hypoxia in viable regions calculated from the number of positive brown pixels and total pixels in viable regions, after setting suitable threshold levels (ImageScope software, Aperio ePathology Solutions, Oxford, UK).
Double immunofluorescent staining was performed on frozen 7-10 µm tumor sections, using the Pharmingen antibody above for CD31 and a mouse anti-mouse α-smooth muscle actin (α-SMA) monoclonal antibody (Cat no. A5228, Sigma-Aldrich, Poole, UK). Biotin-streptavidin technology was used to visualize signals, using Texas red and FITC (Vector Laboratories, Burlingame, CA, USA) to identify CD31 and α-SMA respectively. Tumor sections were viewed using a x10 objective on a Leica DMI 4000B advanced fluorescence microscope and images across the whole of each section captured for quantitation of fluorescence using in-house-developed software.
Briefly, this consisted of thresholding for each fluorescence channel and calculating the amount of α-SMA staining as a % of the amount of CD31 staining for each tumor.
Phospho-receptor tyrosine kinase (RTK) analysis and western blotting
Analysis of RTK phosphorylation in extracts of frozen tumor samples was performed using a mouse phospho-RTK array kit (39 RTK receptors, R&D Systems, Abingdon, UK), following the manufacturer's instructions. Briefly, tumors were homogenized in ice cold PBS, with protease and phosphatase inhibitors, and microcentrifuged with 1% Triton X-100. Protein in supernatants was quantified using the Pierce BCA protein assay kit (Thermo Scientific, Cramlington, UK). Array membranes were incubated with 300 µg of protein overnight at 4 o C, washed and incubated with anti-phosphotyrosine HRP detection antibody for 2 h at room temperature. After washing, arrays were incubated with ECL plus reagents (GE-Healthcare, Chalfont St Giles, UK) and exposed to X-ray film. Developed films were scanned on a Bio-Rad GS-710 densitometer (Bio-Rad Laboratories, Hemel Hempstead, UK) and the ratios of optical densities from SU5416-treated and vehicle-treated tumor samples calculated for assessment of the effect of treatment on each of the RTK phosphorylation levels.
Proteins extracted from tumors in the 6 h group were analysed for phosphorylated and immunoreactive bands were visualized using ELC plus reagents (GE Healthcare, Little Chalfont, UK). Blots were re-probed with an anti-GAPDH antibody (Cell Signaling Technology) and films were scanned as described above. pERK band densities were normalized to GAPDH.
Tumor interstitial fluid pressure
Tumors were treated with two doses of SU5416, as described above. Interstitial fluid pressure (IFP) was measured just prior to the first dose of SU5416 and 24 h after the second dose using the wick-in-needle technique 31 . Briefly, measurements were made using a 23G needle with side-port, connected to a pressure transducer (Model P23XL, Viggo-Spectramed, Windlesham, Surrey) via polyethylene tubing. The whole system was filled with heparinized saline and a nylon 'wick' was placed in the distal portion of the needle to ensure direct contact with the tissue. Measurements were taken in at least three locations in each tumor and the average value was taken to represent the tumor IFP.
Intravital microscopy
Surgery for intravital microscopy was carried out on male SCID mice (12) (13) (14) (15) (16) week-old, 28-32g) under general anaesthesia with Hypnorm (fentanyl citrate and fluanisone; Janssen Animal Health) and Hypnovel (midazolam, Roche, Welwyn
Garden City, UK), as described previously 32 . Briefly, an aluminium window chamber (total weight ∼2g), designed to hold two parallel glass windows 200 µm apart to allow tumor growth, was implanted into a dorsal skin flap. A tumor fragment (∼0.5 mm in diameter; tumor cells expressing VEGF120 or 188) from a donor animal was implanted onto the surgically exposed panniculus muscle of one skin layer and the chamber closed with a glass window. Following recovery from anaesthesia, animals were kept in a warm room, 28-30 °C , until further experimentation. Animals received either SU5416 (50 mg/kg ip) or drug vehicle (DMSO 0.05 ml) starting at day 3 after implant and then every 3 rd to 4 th day until they reached ~ 3mm diameter (1 -2 weeks after surgery), when they were treated with a single dose of CA4P (30 mg/kg iv at 3 mg/ml in 0.9% NaCl) or saline vehicle.
Intravital microscopy was carried out from day 1 after surgery and at various times after administration of CA4P up to 24 h. Transmitted light images were acquired using a Nikon Eclipse E600FN microscope. Vascular length was analysed from images captured with a x10 objective, using in-house developed software, as described previously 32 . Vascular length measurements were made in 2 selected regions of interest (ROIs) in each tumor. A single vessel was defined as a vessel length between two branch-points. Red blood cell velocity (RCV) was also measured from the selected ROIs using a x20 microscope objective. For this, donor red blood cells, acquired via cardiac puncture from donor mice, were labelled with the fluorescent membrane marker, DiI (Molecular Probes, Cambridge Biosciences, UK), as described previously 33 . The labelled cells (0.1 -0.2 ml in PBS) were administered to recipient animals via a tail vein cannula just prior to CA4P/vehicle administration -a single injection being sufficient to visualise the red cells for at least 24 h. 60 s video sequences under epi-fluorescence were captured, at 25 frames/s, using a Sony DSR-30P digital videocassette recorder, from which the full time-course of tumor RCV was calculated using an in-house-developed tracking algorithm 34 . Preliminary data for RCV effects of CA4P at a single time-point (24 h) after CA4P ± SU5416
have been published as conference proceedings 35 
Statistics
A one-way analysis of variance (ANOVA), followed by a Tukey Kramer hsd posttest was used for comparing multiple groups; a students unpaired t-test was used for comparing two independent groups; a paired t-test was used for comparing IFP before and after treatment in the same tumor; a 2-way ANOVA followed by a Bonferroni post-test was used for analyzing multiple groups with more than one variable (treatment and tumor type) (Prism 5 for Mac OS X). Differences between groups, where time-courses were obtained, were analysed using a mixed design ANOVA for repeated measures (SPSS version 11.0.2, for the Apple Macintosh, SPSS Inc). In all cases, differences between groups were described as significant if the probability corresponding to the appropriate statistic was < 0.05. Figure 1 shows the effects of SU5416 on vascular morphology in subcutaneous tumors at 24 and 48h after two doses of SU5416. SU5416 caused a significant reduction in CD31+ vascular area and vascular density per viable field ( Figure 1A & B) . The decreases observed were moderate and did not reach statistical significance for individual pairs of data ( Figure 1A) . The highly dense networks of small calibre vessels in the VEGF188 tumors ( Figure 1A and B) have been reported previously 17 . Morphometric analysis of the shape of individual vessels revealed no effects of SU5416 in either tumor type (data not shown). However, it was noted qualitatively that CD31 staining, especially in VEGF120 tumors, partially filled the lumen of larger vessels in vehicle-treated tumors, whereas this was less apparent in SU5416-treated tumors, as shown in Figure 1B . These larger vessels were more common in VEGF120 than in VEGF188 tumors and in SU5416-treated compared with vehicle-treated tumors ( Figure 1B) . In a different sub-set of vessels, SU5416-induced vascular damage was clearly apparent, as evidenced by regions of tumor cell necrosis surrounding isolated small blood vessels ( Figure 1C ).
Results
Tumor vascular effects of chronic treatment with SU5416
Maturity of the tumor vascular wall was determined quantitatively by measuring the extent of α-SMA staining relative to that of CD31, using immunofluorescence in frozen tumor sections. VEGF188-expressing tumors expressed significantly higher relative levels of α-SMA staining than VEGF120-expressing tumors ( Figure 1D ), indicative of greater vascular maturity, as previously reported 17 . There was no effect of SU5416 treatment on vascular maturity, as measured by α-SMA staining, in either tumor type ( Figure 1D ).
Effects of SU5416 on sub-cutaneous tumors were insufficient to cause any slowing of tumor growth or necrosis induction (Figure 2A & B) . However, there was a differential effect of the drug on IFP in the two tumor types. Figure 2C shows that IFP was higher in untreated VEGF120 than in VEGF188 tumors. IFP in VEGF120
tumors increased further with time, in the vehicle-treated group, which was suppressed by SU5416 treatment, whereas SU5416 treatment had no effect on IFP in VEGF188 tumors ( Figure 2C ). treatment resulted in a significant increase in RCV in VEGF120 tumors, whereas there was no effect in VEGF188 tumors, so that RCV was equalised in the two tumor types after treatment ( Figure 3C ).
Considering both sub-cutaneous and window chamber tumors, there was overall evidence for a small anti-vascular effect of SU5416 in both VEGF120-and VEGF188-expressing tumors. In contrast, SU5416 had no effect on vascular function in VEGF188 tumors (assessed by measurement of RCV), whereas vascular function in VEGF120 tumors was normalised to the level found in vehicle-treated VEGF188
tumors.
Effect of SU5416 pre-treatment on response to the vascular disrupting agent CA4P
Typical low power images of tumors growing in dorsal skin-fold window chambers, at various times following a single dose of CA4P, are shown in Figure 4 .
Quantitative analyses of the effects of CA4P on visible vascular length and RCV are shown in Figure 5 ; these data were derived from two high power regions from each tumor as illustrated in However, the most striking effect was that pre-treatment with SU5416 protected sensitive VEGF120 tumors from the damaging effects of CA4P. In this case, both vascular length and red blood cell velocity recovered to near pre-treatment levels by 24 hours ( Figure 5 ) and the development of hemorrhage at 6 hours and avascular areas at 24 hours were completely abrogated by SU5416 pre-treatment ( Figure 4 ).
Some protection from the effects of CA4P by SU5416 pre-treatment was also observed in VEGF188 tumors, although this was less profound due to their innate resistance to the drug ( Figure 5 ).
Effects of SU5416 pre-treatment on vascular response of s.c. tumors to CA4P
were also studied. Figure 6A shows quantitation of CD31 staining at 3 h after CA4P
administration ± SU5416 pre-treatment. Surprisingly, CA4P treatment tended to increase CD31 staining compared with vehicle-treated tumors, which was significantly abrogated by SU5416 pre-treatment in VEGF120 but not VEGF188 tumors was associated with an acquired resistance to CA4P, such that they responded more like untreated VEGF188 tumors in the window chamber assay. In contrast, SU5416 had no effect on red blood cell velocity in VEGF188 tumors, although response to CA4P was still moderately reduced by pre-treatment with SU5416.
Overall our results suggest that tumors expressing high levels of VEGF120 are particularly susceptible to vascular normalization but that this process renders them insensitive to subsequent vascular disrupting approaches.
SU5416 was previously shown to elicit both a reduction in vascular density and vascular normalization in a rat glioma model transplanted into nude mice 13 and in a hamster melanoma model 14 . A reduction in tumor growth rate was also observed in both these studies. In contrast, Ansiaux et al. 36 reported an absence of vascular remodeling and growth retardation in a transplanted liver tumor and fibrosarcoma mouse model in response to SU5416 treatment, illustrating variability in response to this agent between different tumor types. A daily dosing strategy was employed in all these studies. In the current study, we used an intermittent dosing strategy, consistent with that used clinically and based on evidence that a twice-weekly dosing strategy was as efficacious as a daily dosing strategy, in the A357 human melanoma tumor model 37 . Prolonged biological activity for several days is due to sequestration of this hydrophobic drug in lipid membranes 38 . Clinical trials with SU5416 were unsuccessful, with no or minimal decrease in microvascular density in advanced cancers of mixed origin and inflammatory breast cancer 39, 40 . In our mouse fibrosarcomas, we also showed only moderate anti-angiogenic effects of SU5416, intermediate between those observed in the above pre-clinical studies, with no growth retardation in either tumor type. Window chamber experiments indicated that there was a greater effect of SU5416 in the periphery than in the centre of VEGF120 tumors, which is consistent with observations in other tumor types 41 . In subcutaneously implanted tumors, these effects were consistent with only a small inhibition of VEGFR-2 phosphorylation in both VEGF120 and VEGF188 tumors.
RTK phosphorylation profiling of tumor samples also showed inhibition of other known and less well-known targets of SU5416, which is likely to have contributed to the vascular effects observed.
Vascular normalization was more apparent in VEGF120 tumors than VEGF188 tumors, as exemplified by the increase in red blood cell velocity in the former but not the latter tumor type. Normalization is a complex process that can occur following a range of treatment modalities 42 . Indeed, it was first identified in the 1970s by Le Serve and Hellman 43 following treatment with the anti-metastatic drug razoxane, although it is most commonly associated with anti-angiogenic drugs 5 .
Although the molecular control mechanisms are poorly understood, morphological features can include a moderate reduction in microvascular density, change in vessel diameter and improved pericyte coverage, which may lead to an increase in blood flow, reduced vascular permeability and/or improved oxygenation 5 . In VEGF120 tumors the increase in red blood cell velocity was not associated with any detectable increase in pericyte coverage. This may be due to the known inhibitory effect of SU5416 on PDGFR-β, which was also demonstrated in the current study. On examination of tumor sections stained for CD31, we commonly observed CD31+ cells bridging the lumen of the larger vessels in VEGF120 tumors but less commonly so in VEGF188 tumors. VEGF120 lacks the C-terminal heparin-binding motifs of the larger isoforms and its consequent diffusibility is thought to account for misguidance of endothelial cell migration 44 , which could explain our observation. These endothelial cell 'bridges' were reduced and wider caliber open vessels were more evident following SU5416 treatment. These effects could at least partially explain the increase in red cell velocity observed. In addition, we found higher interstitial fluid pressure (IFP) in VEGF120 compared with VEGF188 tumors, which is most likely related to our previous finding of highly permeable vessel walls in the former 17 .
SU5416 pre-treatment affected IFP differently in the two tumor types, preventing the increase in IFP that was observed over time in VEGF120 tumors. SU5416 also to treatment. * represents a significant difference (P < 0.05; unpaired students t-test).
The right-hand graph shows the effect of SU5416 in tumors, where IFP was obtained 
